Answers are grounded in this paper and cite their sources.
The clinical effect of high-dose (HD) vs medium-dose (MD) ICSs in ICS/LABA/LAMA is unclear. Research Question: What is the clinical effect of HD compared with MD ICSs in ICS/LABA/LAMA treatment of asthma? Study Design and Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations domains. Interpretation: Our results show that HD compared with MD ICS/LABA/LAMA reduces the odds of a severe exacerbation by about 20%. This absolute risk reduction was modest but may be clinically relevant for patients with high baseline exacerbation rates and those with high type 2 inflammation. At both the individual and population level, the use of HD ICS/LABA/LAMA needs to be considered alongside the potential systemic side effects. Clinical Trial Registration: PROSPERO Registry; No.: CRD42025634340; URL: https://www.crd.york.ac.uk/prospero/.
No takes yet. Share an insight, caveat, or question.
Warhurst et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: